Cancer, Chemo, thrombocytopenia
Conditions
Interventions
Experimental group (Routine chemotherapy regimen plus rhinoceros horn and Rehmannia decoction heerzhi pills were given):None
Control Group (Routine chemotherapy regimen):None
Sponsors
San Huan Cancer Hospital, Chaoyang District
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.18-70-year-old patients with solid tumors (breast, lung, esophageal, stomach, colorectal, pancreatic, etc.) who received their first chemotherapy with platinum-based combination chemotherapy, including but not limited to neoadjuvant chemotherapy, adjuvant chemotherapy, first-line therapy, etc. ; 2.ECOG 0-2 points; 3 informed consent, willing to participate in this study; 4 baseline laboratory data: platelet count =100 × 10 ^ 9/l; 5 the main organ functions were tolerant to chemotherapy (liver, heart, kidney, lung, bone marrow function, etc.) , 6 the expected survival time was =12 weeks at screening, and the patients could receive at least one cycle of the current chemotherapy regimen.
Exclusion criteria
Exclusion criteria: 1 excluding patients with primary thrombocytopenia and other hematological disorders, 2 bone marrow involvement, 3 comorbidity with hematological disorders, 4 active bleeding or thrombosis, and 3 screening for thrombocytopenia 5 use of other bone marrow stimulators during treatment; 6 patients with uncontrolled or severe cardiovascular disease; patients unable to take oral medications; 7 pregnant or lactating women; 8 the researchers considered that participation in the trial had a greater risk or potential impact on the health or safety of the subjects.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Platelets; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood biochemical test; | — |
Countries
CHINA
Contacts
Public ContactYurong Zhang
San Huan Cancer Hospital, Chaoyang District
Outcome results
None listed